Najat Khan - 22 Dec 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief R&D Commercial Officer, Director
Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
22 Dec 2025
Net transactions value
-$548,592
Form type
4
Filing time
29 Dec 2025, 17:24:36 UTC
Previous filing
19 Nov 2025
Next filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khan Najat Chief R&D Commercial Officer, Director 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 29 Dec 2025 0002020969

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale $548,592 -124,403 -17% $4.41 611,135 22 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RXRX Stock Option (Right to Buy) 169,851 22 Dec 2025 Class A Common Stock 0 $4.96 Direct F3
holding RXRX Stock Option (Right to Buy) 420,226 22 Dec 2025 Class A Common Stock 0 $7.25 Direct F4
holding RXRX Stock Option (Right to Buy) 993,944 22 Dec 2025 Class A Common Stock 0 $7.34 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $4.30 to $4.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on December 5, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F4 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F5 This option vests as to one fourth (1/4th) of the shares subject to the option on July 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter subject to Reporting Person's continued service to the Issuer through each such vesting date.